The therapeutic role of Olfen-100 SR is relevant for easing symptoms that create noticeable physiological strain. The active ingredient, diclofenac, is relevant within therapeutic areas involving heightened responses, and its use is indicated for managing pain and inflammation. This application is generally observed in clinical settings marked by the heightened patient discomfort often associated with musculoskeletal discomfort.

---

Easing Chronic Pain and Stiffness

This medication is commonly used across conditions presenting with systemic or localized discomfort, such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. It helps address symptom clusters that may become intense or disruptive, like persistent joint aching, swelling, and morning stiffness. By easing these manifestations, it supports general well-being during symptomatic phases and may assist with maintaining comfort. The medicine is also relevant for easing symptoms associated with acute or episodic changes, including flare-ups of inflammatory joint conditions or discomfort following physical injuries like sprains.

Quick Fact	Management of Symptom
Symptom Domain	Pain, Inflammation, and Stiffness
SR Benefit	Supports patients during chronic, persistent symptomatic periods

Olfen-100 SR is intended primarily for use in adults who require maintenance therapy for conditions such as rheumatoid arthritis and osteoarthritis. The 100 mg sustained-release formulation is officially deemed not suitable for children or adolescents.

---

Contraindicated Populations

Use of this medicine is strictly contraindicated and must be avoided in several groups, as defined by regulatory labeling. These absolute exclusions include individuals with active gastrointestinal ulceration, bleeding, or perforation, and patients who have experienced asthma or severe allergic reactions after taking aspirin or other NSAIDs.

Further contraindications apply to those with severe impairment of hepatic (liver) or renal (kidney) function. Individuals with established heart failure (NYHA Class II-IV), ischemic heart disease, or peripheral arterial disease are also strictly prohibited from using this drug, as is use during the last trimester of pregnancy.

---

Restricted or Conditional Use

Use requires particular caution and careful assessment in the elderly, those with a history of certain GI disorders (e.g., Crohn's disease), or patients with uncontrolled hypertension. The medicine is generally not recommended during breastfeeding.

Interactions with Other Medicines and Products

Olfen-100 SR, containing diclofenac, has an official interaction profile defined by government regulatory documents, outlining restrictions and requirements across several substance classes. Co-administration with other systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or analgesic doses of aspirin is not generally recommended due to an increased potential for additive gastrointestinal events. The medicine is formally documented as contraindicated for the relief of pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Specific pharmacokinetic interactions are documented. For instance, the strong CYP2C9 inhibitor Voriconazole is known to cause a significant increase in diclofenac plasma exposure. Conversely, Olfen-100 SR can increase the serum concentration of co-administered agents such as Lithium, Digoxin, and Methotrexate, potentially raising the toxicity risk for these medicines.

Pharmacodynamic interactions primarily involve additive risks. Concomitant use with Anticoagulants, Antiplatelet Agents, Systemic Corticosteroids, and SSRIs/SNRIs increases the documented risk of gastrointestinal bleeding or ulceration. Furthermore, co-administration with Diuretics, ACE Inhibitors, or ARBs can diminish their intended antihypertensive effect and increases the risk of deteriorating renal function. This renal caution is noted to be more significant for the elderly and those with pre-existing renal impairment. Alcohol consumption is also cited in official labeling as a substance that increases the risk of GI bleeding.

Olfen-100 SR (Diclofenac) exerts its effects by directly modulating specific enzyme-mediated signaling pathways at the molecular level. Its mechanism is primarily focused on modulating the production of chemical messengers that trigger and amplify nociceptive and inflammatory responses throughout the body.

Molecular Action: Inhibiting Cyclooxygenase Enzymes

The fundamental action is the inhibition of Cyclooxygenase (COX) enzymes, specifically both the inducible COX-2 and the constitutive COX-1 isoforms. Diclofenac acts as a competitive inhibitor, preventing these enzymes from synthesizing prostaglandins from arachidonic acid. This inhibition is the initial molecular step that shapes all subsequent physiological consequences, resulting in reduced peripheral nociceptive signaling and central thermoregulatory alteration.

Causal Cascade: Dampening Peripheral and Central Signaling

This mechanism involves the downstream physiological effects resulting from the sharp reduction in prostaglandin levels, particularly Prostaglandin E2 ( PGE2). Lower PGE2 concentrations in tissues lead to the desensitization of peripheral pain nerves, thereby reducing the transmission of peripheral nociceptive signals. Centrally, the inhibition of PGE2 synthesis in the hypothalamus contributes to the resetting of the body's thermoregulatory set point, resulting in the physiological adjustment of elevated body temperature.

Formulation Effect: Sustaining the Mechanism

The sustained-release (SR) design influences the kinetics of the mechanism, ensuring the active ingredient is released slowly and continuously over an extended period. This design is engineered to maintain a prolonged inhibitory effect on the COX enzymes and associated pathways. However, this focus on duration means the time required to establish the maximum inhibitory effect is deliberately longer than with immediate-release forms.

How Olfen-100 SR is Used: Official Administration Guidelines

Olfen-100 SR (Diclofenac 100 mg Sustained-Release) is an oral medication used according to standardized instructions to ensure proper systemic delivery.

---

Official Dosing and Method of Administration

The fundamental regimen for the prolonged-release 100 mg form is once daily oral administration for adults. Adherence to a specific intake method is critical to preserve the extended-release mechanism, which is designed for continuous, long-lasting control.

Usage Parameter	Official Labeled Instruction
Route and Frequency	Oral, once daily.
Standard Adult Dose	100 mg of the prolonged-release form per day.
Maximum Daily Dose	The recommended maximum total daily dose for diclofenac is 150 mg, which is achieved by supplementing the 100 mg SR dose with an immediate-release form if needed.

---

Administration Conditions and Constraints

For proper administration, the tablet must be swallowed whole with liquid and should not be divided, crushed, or chewed. It is recommended that the dose be taken preferably with or after food. Some guidelines suggest taking the dose in the evening if symptoms are most severe during the night or morning.

Population-Specific Use

Administration guidelines include rules for specific patient groups:

• Pediatric Use: The 100 mg prolonged-release tablet/capsule is not suitable for children and adolescents.
• Older Adults: The lowest effective dosage is recommended, particularly for frail patients or those with low body weight.
• Long-Term Cardiovascular Risk: The lowest effective dose must be used for the shortest duration possible, with a recommended dose restriction of 100 mg per day if treated for more than four weeks.

Research Evidence / Overview of Studies for Olfen-100 SR

The evidence base for Olfen-100 SR is built upon research that was studied for its active ingredient, diclofenac, particularly in its sustained-release (SR) format. This research describes the patterns observed in patients with chronic inflammatory conditions. This overview aims to outline what research has been conducted and what questions still remain, strictly avoiding clinical guidance or therapeutic advice.

---

Evidence for Use in Chronic Inflammatory Joint Conditions

The research base primarily utilized Randomized Controlled Trials (RCTs) and Systematic Reviews; these studies examined the drug's role in conditions characterized by fluctuating or episodic manifestations such as Rheumatoid Arthritis (RA) and Osteoarthritis (OA). These conditions are typically marked by outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level.

In these studies, researchers examined patient-reported measurements of pain intensity and objective scales that measure changes in physical function. Dedicated pharmacokinetic studies were also conducted to evaluate the formulation's intended drug delivery. These research explored the drug's absorption rate and data show patterns related to the sustained therapeutic levels in the bloodstream.

Research describes patterns observed in the studies regarding measurements of pain and functional capacity. Research focusing on symptomatic measurements often centers on short-term (e.g., 2- to 4-week) intervals. Furthermore, the evidence does not provide insight into whether the drug affects or changes the underlying structural progression of joint diseases.

---

Research Focus on Ankylosing Spondylitis (AS)

The sustained-release formulation was also evaluated in studies involving adult patients with Ankylosing Spondylitis (AS), a condition involving periods of heightened symptoms related to spinal inflammation. Researchers used RCTs that examined continuous versus on-demand dosing of the medicine.

While trials report how symptoms evolved in the observed populations, the evidence is non-conclusive and varied regarding the long-term patterns of radiographic progression in studies that compared continuous versus intermittent dosing. The question of structural change remains uncertain.

---

What the Research Does Not Fully Address

The research examined outcomes related to physical discomfort; however, evidence does not determine a role in preventing or slowing the structural progression of chronic joint conditions. Furthermore, comparative evidence is lacking in the form of large-scale, long-term RCTs designed to explicitly assess the full range of effects of this drug against all other traditional NSAID compounds.

It is important to remember that research provides context but not individual predictions. Study results reflect the specific conditions under which they were conducted, meaning the results apply only to the populations studied, and the research does not determine whether an individual will respond similarly.

Key Studies & References

1. Non-steroidal Anti-inflammatory Drugs Are Unlikely to Inhibit Radiographic Progression of Ankylosing Spondylitis: A Systematic Review

Common questions about Olfen-100 SR (FAQ)

---

Q: What are the primary conditions Olfen-100 SR is authorized to treat?

According to official regulatory documents, Olfen-100 SR is indicated for the symptomatic treatment of inflammatory and degenerative forms of rheumatism. This includes conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Its therapeutic role is the systemic reduction of associated pain and inflammation.

Q: Can taking Olfen-100 SR cause fluid retention or swelling in the hands and feet?

The official product information states that diclofenac-containing medicines may be associated with fluid retention and edema (swelling). This is listed in official documents as a commonly reported side effect. Fluid retention may lead to swelling in the hands, ankles, or feet.

Q: Are there warnings about Olfen-100 SR affecting hearing, like causing ringing in the ears?

Official regulatory labeling notes that effects on hearing are potential adverse reactions associated with diclofenac. These effects, such as tinnitus (a ringing sensation in the ears), are noted in official labeling as potential adverse reactions.

Q: Why is it important to tell a doctor about all other medicines, including herbal supplements?

Official warnings indicate that Olfen-100 SR is known to interact with many substance classes, including certain prescription medicines and alcohol. This carries a documented risk of severe side effects. This highlights the need for a healthcare provider to review all concomitant use before treatment begins.

Q: What are the signs of a severe gastrointestinal side effect, such as internal bleeding?

Official product information describes signs that may signal a severe gastrointestinal event. These signs can include persistent stomach pain, vomiting material that looks like coffee grounds, or passing stools that are black and tarry.

Q: Can Olfen-100 SR temporarily mask the common signs or symptoms of an infection?

According to official safety information, this medicine, like other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), can mask the symptoms of an infection. The mechanism involves reducing fever and inflammation, which are key physiological markers that signal an underlying health issue.

Q: Why might a physician prescribe the 100mg SR capsule instead of a standard immediate-release tablet?

The sustained-release (SR) form is designed to provide continuous, long-lasting relief, particularly suitable for symptoms that peak at night or early morning. This formulation simplifies a prolonged treatment regimen by allowing for convenient once-daily administration.

Q: Is there any known effect of Olfen-100 SR on fertility or the ability to become pregnant?

Official product information indicates that taking this medicine, like other NSAIDs, may potentially impair female fertility. Regulatory documents state that this medicine is generally not used by women who are attempting to conceive. This effect is expected to be reversible once the medication is stopped.

Q: What does the product information say about the use of Olfen-100 SR if a person has diabetes?

Regulatory warnings state that patients with pre-existing cardiovascular risk factors, which often includes diabetes, must be assessed carefully before and during treatment. For these individuals, official guidelines outline the principle of using the lowest effective dose for the shortest duration possible.

Q: Are there specific control tests, like blood or urine tests, that may be required during long-term Olfen-100 SR use?

For patients on long-term treatment with Olfen-100 SR, regulatory information recommends periodic medical monitoring. This periodic monitoring typically involves assessing liver function, kidney function, and blood count.

Q: Does Olfen-100 SR contain lactose or any other common allergens?

Regulatory documents state that the formulation of some diclofenac-containing tablets includes the excipient lactose monohydrate. Regulatory labeling indicates that patients with rare hereditary issues involving lactose or galactose intolerance are advised to avoid this medicine.

Q: Is Olfen-100 SR used to treat gout, and if so, how does it help?

According to the official therapeutic indications, diclofenac is authorized for the treatment of acute attacks of gout. Its role in this context is the systemic reduction of the associated pain and inflammation.

Q: What warnings are given about using Olfen-100 SR if a patient has recently had or is scheduled for GI surgery?

Regulatory warnings outline that close medical surveillance and particular caution are necessary when this medicine is used immediately following major gastrointestinal surgery. This is due to the potential for increased risk of adverse GI events.

Storage and Disposal of Olfen-100 SR

Olfen-100 SR must be stored under specific environmental controls to maintain its stability. The medication must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).

Storage Requirements

The tablets must be protected from both moisture and excessive heat and should remain in the original container. It is a mandatory requirement to keep Olfen-100 SR out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets should be disposed of using a local drug take-back program whenever possible. Olfen-100 SR must not be flushed down the toilet or poured into a drain. If household disposal is necessary, tablets must be mixed with an undesirable substance and placed in a sealed bag before disposal in the trash.